An effective way to generate human CD4+ and CD8+ T cell responses is by presenting antigens on dendritic dells (DCs), a system of antigen presenting cells (APCs) that stimulate innate and adaptive immune responses. Immunization strategies that utilize or target human DCs to enhance immunity in chronic HIV infection have shown promise in previous studies, but further research is required to optimize DC vaccine candidates. Ideally, a DC-targeting vaccine vector should deliver relevant HIV antigens for presentation, while concurrently activating DCs to upregulate surface costimulatory molecules and produce pro Th1 cytokines in order to prime HIV-specific polyfunctional CD4+ and CD8+ T cell responses. Recombinant killed but metabolically active Listeria Monocytogenes vectors may fulfill these criteria, while offering potential advantages in terms of both immunogenicity and safety when compared with various attenuated viral and bacterial vectors. In the proposed research, the use of a recombinant killed but metabolically active Listeria Monocytogenes expressing HIV-1 gag (KBMA Lm-gag) will be investigated as an antigen loading and activation/maturation platform for DCs to evaluate its potential use in DC vaccine formulations for chronic HIV infection.
The specific aims are to: (1) assess activation/maturation and efficiency of antigen presentation of DCs derived from HIV seropositive donors following infection with KBMA Lm-gag;(2) evaluate the ability of KBMA Lm-gag infected DCs derived from HIV seropositive patients to prime naive T cells to form polyfunctional HIV-1 gag-specific CD4+ and CD8+ T cells that possess high functional avidity;and (3) investigate whether pre-existing immunity to Lm impacts responses elicited by KBMA lm-gag infected DCs in terms of immunogenicity, immune activation, and susceptibility of CD4+ T cells to HIV infection. These studies will help determine whether KBMA Lm-gag may serve as an exciting new vector for HIV immunotherapy that utilizes or targets DCs to facilitate control of HIV infection.

Public Health Relevance

The field of HIV vaccinology has recently suffered set-backs, inspiring the investigation of novel modes of antigen delivery in order to stimulate HIV-specific immunity. In order to move forward from this point, we have applied aspects of the knowledge gained from failed attempts to the design and evaluation of the construct utilized in the proposed study.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08AI084578-02
Application #
7922726
Study Section
Acquired Immunodeficiency Syndrome Research Review Committee (AIDS)
Program Officer
Butler, Robert C
Project Start
2009-09-01
Project End
2014-07-31
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
2
Fiscal Year
2010
Total Cost
$131,900
Indirect Cost
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Fernandez, Melissa Victoria; Miller, Elizabeth; Krammer, Florian et al. (2016) Ion efflux and influenza infection trigger NLRP3 inflammasome signaling in human dendritic cells. J Leukoc Biol 99:723-34
Norton, T D; Miller, E A; Bhardwaj, N et al. (2015) Vpx-containing dendritic cell vaccine induces CTLs and reactivates latent HIV-1 in vitro. Gene Ther 22:227-36
Miller, Elizabeth A; Gopal, Ramya; Valdes, Vanessa et al. (2015) Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection. AIDS 29:1287-96
Miller, Elizabeth A; Spadaccia, Meredith R; Norton, Thomas et al. (2015) Attenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus. AIDS Res Hum Retroviruses 31:127-36
Miller, Elizabeth; Spadaccia, Meredith; Sabado, Rachel et al. (2015) Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy. Vaccine 33:388-95
Manches, Olivier; Frleta, Davor; Bhardwaj, Nina (2014) Dendritic cells in progression and pathology of HIV infection. Trends Immunol 35:114-22
Sabado, Rachel Lubong; Miller, Elizabeth; Spadaccia, Meredith et al. (2013) Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy. J Vis Exp :
Miller, Elizabeth; Bhardwaj, Nina (2013) Dendritic cell dysregulation during HIV-1 infection. Immunol Rev 254:170-89
Miller, Elizabeth A; Spadaccia, Meredith R; O?Brien, Meagan P et al. (2012) Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway. J Acquir Immune Defic Syndr 61:535-44